Brief: Baudax Bio Announces Positive Outcome Of Interim Analysis Of Phase Ii Randomized Trial For Bx1000
24/01/2023 13:24
Jan 24 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS
OF
PHASE II RANDOMIZED TRIAL FOR BX1000
* BAUDAX BIO-BLINDED INTERIM ANALYSIS DIDN'T RESULT IN
DECISION TO
DROP ANY OF 4 STUDY GROUPS NOR ANY DECISION TO ADJUST PLANNED
STUDY ENROLLMENT NUMBERS
* BAUDAX BIO INC - STUDY TREATMENTS WERE GENERALLY WELL
TOLERATED
WITH NO OCCURRENCE OF SEVERE OR SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX9MdvHm
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer